Anna Tsapara

Irakleion, ESYE43, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

IOA-244, a novel p110δ PI3K inhibitor, blocks breast tumour progression on either mono- or combined-therapy.

IOA-244, a novel p110δ PI3K inhibitor, blocks breast tumour progression on either mono- or combined-therapy.

Journal: Cell death discovery

Published: October 28, 2025

Chorein Regulates Key Osteoblast Genes in UMR-106 Cells.

Chorein Regulates Key Osteoblast Genes in UMR-106 Cells.

Journal: Cell biochemistry and biophysics

Published: October 24, 2025

A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer.

A combined opposite targeting of p110δ PI3K and RhoA abrogates skin cancer.

Journal: Communications biology

Published: March 07, 2023

Identification of Structural Elements of the Lysine Specific Demethylase 2B CxxC Domain Associated with Replicative Senescence Bypass in Primary Mouse Cells.

Identification of Structural Elements of the Lysine Specific Demethylase 2B CxxC Domain Associated with Replicative Senescence Bypass in Primary Mouse Cells.

Journal: The protein journal

Published: April 10, 2020

The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.

The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.

Journal: Cancer biology & therapy

Published: March 17, 2020

The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.

The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: February 06, 2018

The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.

The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.

Journal: Biochimica et biophysica acta. Molecular cell research

Published: September 25, 2017

Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells.

Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: May 10, 2017

Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor.

Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor.

Journal: Oncotarget

Published: November 03, 2015

Chorein Sensitive Arrangement of Cytoskeletal Architecture.

Chorein Sensitive Arrangement of Cytoskeletal Architecture.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: July 08, 2015

Chorein addiction in VPS13A overexpressing rhabdomyosarcoma cells.

Chorein addiction in VPS13A overexpressing rhabdomyosarcoma cells.

Journal: Oncotarget

Published: July 31, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026